Pegaspargase: An alternative?

Annals of Pharmacotherapy

Volumn 31, Issue 5, 1997, Pages 616-624

  Holle, Lisa M ^a  

^a Baptist Medical Center   (United States)

Author keywords

acute lymphocytic leukemia; L asparaginase; pegaspargase

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; CYTARABINE; METHOTREXATE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENZYME ACTIVITY; ESCHERICHIA COLI; HUMAN; HYPERGLYCEMIA; HYPOFIBRINOGENEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROLOGIC DISEASE; PANCREATITIS; PECTOBACTERIUM CAROTOVORUM; PRIORITY JOURNAL; REVIEW;

EID: 0030973214     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100517     Document Type: Review

References (30)

1. Duncan R, Spreafico F. Polymer conjugates - pharmacokinetic considerations for design and development. Clin Pharmacokinet 1994;27:290-306.
2. Wada H, Imamura I, Sako M, Katagiri S, Tarui S, Nishimura H, et al. Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann N Y Acad Sci 1990; 613:95-108.
3. Yoshimoto T, Nishimura H, Saito Y, Sakurai K, Kamisaki Y, Wada H, et al. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res 1986;77:1264-70.
4. Chabner BA, Loo TL. Enzyme therapy: L-asparaginase. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: principles and practice. Philadelphia: Lippincott-Raven, 1996:485-92.
5. Ho DH, Brown NS, Yen A, Holmes R, Keating M, Abuchowski A, et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 1986;14:349-52.
6. Asselin BL, Whitin JC, Coppola DJ, Rupp IR, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-6.
7. Park YK, Abuchowski A, Davis S, Davis F. Pharmacology of Escherichia coli L-asparaginase polyethylene glycol adduct. Anticancer Res 1981;1:373-6.
8. Capizzi RL, Bertino JR, Handschumacher RE. L-Asparaginase. Ann Rev Med 1970;21:433-44.
9. Kurtzberg J. A new look at pegaspargase and other asparaginases in hematological malignancies (abstract). Cancer Invest 1994;12(suppl 1):59.
10. Kurtzberg J, Asselin B, Poplack D, Grenbanier A, Chen R, Franklin A, et al. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy (abstract). Proc Am Assoc Cancer Res 1993;34:1807.
11. Kurtzberg J, Asselin B, Berg S, Graham ME, Balis FM, Poplack D. Pharmacokinetics of PEG-L-asparaginase in pediatric patients with known hypersensitivity to native L-asparaginase (abstract). Proc Annu Meet Am Assoc Cancer Res 1992;33:210.
12. Abuchowski A, Kazo GM, Verhoest CR Jr, Van Es T, Kafkewitz D, Nucci ML, et al. Cancer therapy with chemically modified enzymes. I. Antitumor polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984;7:175-86.
13. 2-ASP) in two patients with hematological malignancies. Leuk Res 1991;15:525-30.
14. Muss HB, Spell N, Scudiery D, Capizzi RL, Cooper R, Cruz J, et al. A Phase II trial of pegaspargase in the treatment of non-Hodgkin's lymphoma. Invest New Drugs 1990;8:125-30.
15. Kurtzberg J, Moore JO, Scudiery D, Franklin A. A Phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukemias (abstract). Proc Am Assoc Cancer Res 1988; 29:219.
16. Kurtzberg J, Friedman H, Asselin B, Schultz W, Krishcer J, Scudiery D, et al. The use of polyethylene glycol-conjugated-L-asparaginase (PEG-ASP) in pediatric patients with prior hypersensitivity to native L-asparaginase (abstract). Proc Am Soc Clin Oncol 1990;9:848.
17. Capizzi RL. Asparaginase revisited. Leuk Lymphoma 1993;10:147-50.
18. Ettinger LJ, Kurtzberg J, Voute P, Jurgens H, Halpern SL. An open-label, multicenter study of polyethylene glycol L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995;67:1176-81.
19. Sutow WW, Garcia F, Starling KA, Williams TE, Lane DM, Gehan EA. L-Asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Group. Cancer 1971;28:819-24.
20. Package insert. Oncaspar (pegaspargase). Collegeville, PA: Rhône-Poulenc Rorer, November 1994.
21. Dorr RT, Von Hoff DD. Drug monographs - asparaginase. In: Dorr RT, Von Hoff DD, eds. Cancer chemotherapy handbook. Norwalk, CT: Appleton and Lange, 1994:201-9.
22. Capizzi RL, Holcenberg JS. Asparaginase. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. Philadelphia: Lea and Febiger, 1993:796-805.
23. Weiss R. Hypersensitivity reactions. Semin Oncol 1992;19:458-77.
24. Abshire T, Pollock B, Billett A, Bradley P, Buchanan G. Weekly polyethylene glycol conjugated pegaspargase (ASP) produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia (rALL): a pediatric oncology study (abstract). Proc Am Soc Clin Oncol 1995;14:344.
25. Asselin B, Gelber R, Sallan S. Relative toxicity of E. coli L-asparaginase (ASP) and pegaspargase (PEG) in newly diagnosed childhood acute lymphoblastic leukemia (abstract). Blood 1995;86(suppl 1):177a.
26. Edelstein EG, ed. First Databank blue book 1996. New York: Hearst Corp., 1996:138,292.
27. Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary 1995;30(7):388-93.
28. Hoelzer D, Thiel E, Löffler H, Büchner T, Ganser A, Heil G, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1987;69:1242-8.
29. Linker CA, Levitt LJ, O'Donnell M, Ries CA, Link MP, Forman SJ, et al. Improved results of treatment of adult acute lymphoblastic leukemia. Blood 1987;69:1242-8.
30. Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. Blood 1994;6:267-74.